Firehawk Liberty™ Receives Registration Approval in Colombia

Bogota, Colombia - Recently, the Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (‘Firehawk Liberty™’), developed by Shanghai MicroPort® Medical Group Co., Ltd. (MicroPort®), has received registration approval from the National Institute for Drug and Food Surveillance of Columbia.

Firehawk Liberty™ is a drug-eluting stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy.

Firehawk Liberty™ allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug, whilst significantly reducing the drug loading. In addition, it features innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the vessel wall apposition.

Firehawk Liberty™ is currently approved in a number of countries and regions, including Belarus, Saudi Arabia, South Korea, Brazil, India and the European Union. In the future, MicroPort® will continue its commitment to provide more high-quality and innovative total medical solutions for patients with coronary artery diseases around the world.

About Shanghai Microport Medical (Group) Co., Ltd

Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®) is a subsidiary of MicroPort Scientific Corporation (00853.HK). MicroPort® has grown over the years to become one of the leading manufacturers of medical devices. Its products cover a wide range of medical fields, including cardio rhythm management, orthopedic devices, vascular intervention, surgical management, and more. As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA.